What is Arocell?
Saving lives with diagnostics.
– We provide knowledge to decision.
– AroCell Group consist of AroCell AB and IDL Biotech.
Further strengthening partnerships in Southeast Asia
In the beginning of May, IDL Diagnostics team visited our distributors in Indonesia and the Philippines as part of our ongoing efforts to strengthen local partnerships and stay closely connected to our markets. During our time in Jakarta, we had an in-depth discussion...
Meet Gustav Sten – IDL Diagnostics’ new CEO in an interview with Redeye
In the interview, Gustav Sten talks about his new role, his journey within the company, and reflects on the development under Anders Hultman’s leadership. He also shares his priorities going forward, with a focus on commercialization and continued growth.
Gustav Sten appointed CEO of IDL Diagnostics
IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the position on May 28, immediately following the Annual General Meeting, succeeding Anders Hultman. Gustav Sten...
UBC® Rapid | Bladder Cancer detection
A powerful Doctors-office test (Point-of-Care), for aid in the diagnosis and monitoring of bladder cancer. Read more about UBC® Rapid
TUBEX® TF | Rapid Typhoid Detection
A rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonella typhi. Read more about TUBEX® TF
TK 210 ELISA | Cell Proliferation Biomarker
The AroCell TK 210 ELISA kit used for therapy response in subjects with many forms of cancer including several solid tumors. Read more about TK 210 ELISA
Tumor markers licensed to strategic partners
Arocell is constantly building partnerships for establishing projects and developing new products to expand its portfolio. Read More about tumor markers
Press Releases
About us
We provide knowledge to decision.
IDL Diagnosticsis a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
